Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer

International Journal of Urology

Volumn 14, Issue 3, 2007, Pages 264-267

  Nishimura, Kenji ^a   Arichi, Naoko ^a   Tokugawa, Shigeki ^a   Yoshioka, Iwao ^a   Kishikawa, Hidefumi ^a   Ichikawa, Yasuji ^a  

^a Hyogo Prefectural Nishinomiya Hospital   (Japan)

Author keywords

Bicalutamide; Flutamide; Hormone refractory prostate cancer; Maximum androgen blockade (MAB); Second line agent

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REFRACTORY PERIOD; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ENDOSONOGRAPHY; FLUTAMIDE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 33947267982     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01681.x     Document Type: Article

References (10)

1. Nishimura K, Nonomura N, Yasunaga Y et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000; 89: 2570-6.
2. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46: 142-8.
3. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int. 2004; 93: 1177-82.
4. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J. Urol. 2004; 171: 679-83.
5. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int. 2005; 96: 791-5.
6. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-8.
7. Crawford ED, Eisenberger MA, Mcleod DG et al. A controlled trial leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 1989; 321: 419-24.
8. Kotake T, Usami M, Akaza H et al. Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: multicenter randomized , controlled trial in Japan. Zoladex Study Group. Jpn. J. Clin. Oncol. 1999; 29: 562-70.
9. Akaza H, Yamaguchi A, Matsuda T et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn. J. Clin. Oncol. 2004; 34: 20-8.
10. Mcleod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18-27.